Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical company Pharmaxis has received approval to market Aridol from the Swiss therapeutic regulatory agency Swissmedic.
Subscribe to our email newsletter
Aridol will be distributed in Switzerland by Trimedal, a specialist respiratory and allergy pharmaceutical company based in Zurich, Switzerland. Pricing for Aridol in Switzerland is included under an existing reimbursement code so marketing may commence immediately.
Aridol is indicated for measuring airway hyperresponsiveness and within Europe is now approved in 13 countries – Denmark, Finland, France, Germany, Greece, Ireland, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the UK.
According to the company, Aridol, a simple-to-use airways inflammation test, is a dry powder administered to patients’ lungs via a small hand-held inhaler. Doctors can use the results of this test to identify airway hyperresponsiveness – a hallmark of asthma. Medications can be adjusted according to the severity of the disease.
Alan Robertson, CEO of Pharmaxis, said: “This level of innovation has attracted the attention of two multinational Pharma companies who are currently funding studies in Switzerland that utilize Aridol to diagnose asthma and chronic obstructive pulmonary disease patients who will respond to inhaled corticosteroids.”